Women's Public Health Research, School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia 3168.
Trends Endocrinol Metab. 2012 Oct;23(10):533-43. doi: 10.1016/j.tem.2012.07.001. Epub 2012 Aug 30.
Though widely used, there is uncertainty about the effectiveness and adverse effects of metformin and clomiphene citrate (CC) for infertility in polycystic ovary syndrome (PCOS). A systematic review (SR) of the best available evidence suggests that both CC and metformin are better than placebo for increasing ovulation and pregnancy rates, but CC is more effective than metformin for ovulation, pregnancy and live-birth rates, in PCOS patients with body mass index (BMI) >30. A combination of CC and metformin is superior to either metformin alone or CC alone, depending on the BMI and CC sensitivity of the patient. This SR provides key messages to guide clinicians and consumers on the use of these interventions in different subgroups of women with PCOS.
虽然二甲双胍和枸橼酸氯米酚（CC）被广泛用于多囊卵巢综合征（PCOS）患者的不孕治疗，但对于其有效性和不良反应仍存在不确定性。一项针对最佳现有证据的系统评价（SR）表明，CC 和二甲双胍在增加排卵率和妊娠率方面均优于安慰剂，但对于 BMI＞30 的 PCOS 患者，CC 在排卵率、妊娠率和活产率方面的效果优于二甲双胍。CC 联合二甲双胍的效果优于单独使用二甲双胍或 CC，具体取决于患者的 BMI 和 CC 敏感性。本 SR 提供了关键信息，以指导临床医生和消费者在 PCOS 不同亚组患者中使用这些干预措施。
